Login to Your Account



Other news to note


Friday, February 21, 2014
Theravance Inc., of South San Francisco, and Glaxosmithkline plc, of London, said the European Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for umeclidinium/vilanterol (UMEC/VI), under the proposed brand name Anoro, as a once-daily maintenance bronchodilator to relieve symptoms in adults with chronic obstructive pulmonary disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription